Christopher D Fletcher
Overview
Explore the profile of Christopher D Fletcher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
3102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang J, McQuinn D, Hyun M, Kim K, Kenkre V, Rajguru S, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Oct;
25(3):188-198.
PMID: 39477701
Introduction: Obinutuzumab is hypothesized to improve progression-free survival (PFS) combined with bendamustine induction in mantle cell lymphoma (MCL). Measurable-residual disease (MRD) testing may predict benefit from maintenance therapy. Methods: Adults...
2.
Britt E, Qing X, Votava J, Lika J, Wagner A, Shen S, et al.
Proc Natl Acad Sci U S A
. 2024 Sep;
121(39):e2321212121.
PMID: 39284072
Neutrophils utilize a variety of metabolic sources to support their crucial functions as the first responders in innate immunity. Here, through in vivo and ex vivo isotopic tracing, we examined...
3.
Morris B, Merfeld E, Burr A, Bradley K, Fletcher C
Adv Radiat Oncol
. 2024 May;
9(7):101524.
PMID: 38799107
Purpose: Approximately 30% of patients with diffuse large B cell lymphoma (DLBCL) will develop relapsed or treatment-refractory disease after primary chemotherapy. Patients unable to undergo aggressive chemotherapy and stem cell...
4.
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, et al.
J Natl Compr Canc Netw
. 2024 Apr;
22(3):175-204.
PMID: 38626800
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic...
5.
Britt E, Qing X, Votava J, Lika J, Wagner A, Shen S, et al.
bioRxiv
. 2023 Oct;
PMID: 37808750
Neutrophils - the first responders in innate immunity - perform a variety of effector functions associated with specific metabolic demand. To maintain fitness and support functions, neutrophils have been found...
6.
Lennerz J, Pantanowitz L, Amin M, Eltoum I, Hameed M, Kalof A, et al.
Nat Med
. 2022 Oct;
28(12):2453-2455.
PMID: 36266514
No abstract available.
7.
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, et al.
J Natl Compr Canc Netw
. 2022 Jun;
20(6):622-634.
PMID: 35714675
The treatment landscape of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has significantly evolved in recent years. Targeted therapy with Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors has emerged as...
8.
Acosta A, Al-Obaidy K, Sholl L, Dickson B, Lindeman N, Hirsch M, et al.
Am J Surg Pathol
. 2022 Jan;
46(5):701-712.
PMID: 35034041
In testicular germ cell tumors (TGCTs), components with nonspecific sarcomatous features that express keratins and glypican 3 are classified as sarcomatoid yolk sac tumor (SYST). SYST is most frequently seen...
9.
Acosta A, Sholl L, Marino-Enriquez A, Dal Cin P, Dickson B, Gordetsky J, et al.
Mod Pathol
. 2021 Sep;
34(11):2082-2083.
PMID: 34497361
No abstract available.
10.
Antonescu C, Dickson B, Zhang L, Sung Y, Fletcher C
Mod Pathol
. 2021 Apr;
34(8):1541-1546.
PMID: 33859361
Despite extraordinary advances in the molecular characterization of soft tissue tumors as a result of the widespread application of next generation sequencing in clinical practice, a subset of lesions remain...